The EBMT activity survey report 2017: A focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies

Hematopoietic cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants done in Europe and associated countries continues to rise with 45,418 HCT in 41,100 patients [(17,155 allogeneic (42%) and 23,945 autologous (58%)] reporte...

Descripción completa

Detalles Bibliográficos
Autores: Passweg, Jakob R., Baldomero, Helen, Basak, Grzegorz W., Chabannon, Christian, Corbacioglu, Selim, Duarte Palomino, Rafael, Kuball, Jürgen, Lankester, Arjan, Montoto, Silvia, Peffault de Latour, Régis, Snowden, John A., Styczynski, Jan, Yakoub-Agha, Ibrahim, Arat, Mutlu, Mohty, Mohamad, Kröger, Nicolaus
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:repositorio.uam.es:10486/688585
Acceso en línea:http://hdl.handle.net/10486/688585
https://dx.doi.org/10.1038/s41409-019-0465-9
Access Level:acceso abierto
Palabra clave:Hematopoietic cell transplantation (HCT)
Allogeneic
Myeloid malignancies
Lymphoid malignancies
Anemia patients
Hemoglobinopathies
Medicina
id ES_ce2cd583a9ed39eafb2ba40efb014433
oai_identifier_str oai:repositorio.uam.es:10486/688585
network_acronym_str ES
network_name_str España
repository_id_str
spelling The EBMT activity survey report 2017: A focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapiesPassweg, Jakob R.Baldomero, HelenBasak, Grzegorz W.Chabannon, ChristianCorbacioglu, SelimDuarte Palomino, RafaelKuball, JürgenLankester, ArjanMontoto, SilviaPeffault de Latour, RégisSnowden, John A.Styczynski, JanYakoub-Agha, IbrahimArat, MutluMohty, MohamadKröger, NicolausHematopoietic cell transplantation (HCT)AllogeneicMyeloid malignanciesLymphoid malignanciesAnemia patientsHemoglobinopathiesMedicinaHematopoietic cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants done in Europe and associated countries continues to rise with 45,418 HCT in 41,100 patients [(17,155 allogeneic (42%) and 23,945 autologous (58%)] reported by 683 centers in 50 countries in 2017. Main indications were myeloid malignancies 10,147 (25%; 96% allogeneic), lymphoid malignancies 26,488 (64%; 19% allogeneic), solid tumors 1,607 (3.9%; 2% allogeneic), and nonmalignant disorders 2,667 (7%; 81% allogeneic). Trends in donor choice seen before continue, with growing numbers of haploidentical HCT and decreasing use of cord blood. Of interest is that after many years of continued growth, the number of patients receiving an allogeneic HCT for marrow failure is decreasing slightly (p < 0.001). Such a change may be explained by the use of thrombopoietin analogs in aplastic anemia patients. Other nonmalignant indications, however continue to grow, most importantly HCT for hemoglobinopathies by 36%, equally for thalassemias and sickle cell disease. Non-HCT cell therapies have increased by 28% since 2015 and genetically modified T cells is type of cell therapy with the fastest growth. These annual reports reflect current activity and trends and are useful for health-care planning.Springer NatureDepartamento de MedicinaFacultad de Medicina20192019-02-06research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10486/688585https://dx.doi.org/10.1038/s41409-019-0465-9reponame:Biblos-e Archivo. Repositorio Institucional de la UAMinstname:Universidad Autónoma de MadridInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:repositorio.uam.es:10486/6885852026-06-23T12:46:27Z
dc.title.none.fl_str_mv The EBMT activity survey report 2017: A focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies
title The EBMT activity survey report 2017: A focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies
spellingShingle The EBMT activity survey report 2017: A focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies
Passweg, Jakob R.
Hematopoietic cell transplantation (HCT)
Allogeneic
Myeloid malignancies
Lymphoid malignancies
Anemia patients
Hemoglobinopathies
Medicina
title_short The EBMT activity survey report 2017: A focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies
title_full The EBMT activity survey report 2017: A focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies
title_fullStr The EBMT activity survey report 2017: A focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies
title_full_unstemmed The EBMT activity survey report 2017: A focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies
title_sort The EBMT activity survey report 2017: A focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies
dc.creator.none.fl_str_mv Passweg, Jakob R.
Baldomero, Helen
Basak, Grzegorz W.
Chabannon, Christian
Corbacioglu, Selim
Duarte Palomino, Rafael
Kuball, Jürgen
Lankester, Arjan
Montoto, Silvia
Peffault de Latour, Régis
Snowden, John A.
Styczynski, Jan
Yakoub-Agha, Ibrahim
Arat, Mutlu
Mohty, Mohamad
Kröger, Nicolaus
author Passweg, Jakob R.
author_facet Passweg, Jakob R.
Baldomero, Helen
Basak, Grzegorz W.
Chabannon, Christian
Corbacioglu, Selim
Duarte Palomino, Rafael
Kuball, Jürgen
Lankester, Arjan
Montoto, Silvia
Peffault de Latour, Régis
Snowden, John A.
Styczynski, Jan
Yakoub-Agha, Ibrahim
Arat, Mutlu
Mohty, Mohamad
Kröger, Nicolaus
author_role author
author2 Baldomero, Helen
Basak, Grzegorz W.
Chabannon, Christian
Corbacioglu, Selim
Duarte Palomino, Rafael
Kuball, Jürgen
Lankester, Arjan
Montoto, Silvia
Peffault de Latour, Régis
Snowden, John A.
Styczynski, Jan
Yakoub-Agha, Ibrahim
Arat, Mutlu
Mohty, Mohamad
Kröger, Nicolaus
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Departamento de Medicina
Facultad de Medicina
dc.subject.none.fl_str_mv Hematopoietic cell transplantation (HCT)
Allogeneic
Myeloid malignancies
Lymphoid malignancies
Anemia patients
Hemoglobinopathies
Medicina
topic Hematopoietic cell transplantation (HCT)
Allogeneic
Myeloid malignancies
Lymphoid malignancies
Anemia patients
Hemoglobinopathies
Medicina
description Hematopoietic cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants done in Europe and associated countries continues to rise with 45,418 HCT in 41,100 patients [(17,155 allogeneic (42%) and 23,945 autologous (58%)] reported by 683 centers in 50 countries in 2017. Main indications were myeloid malignancies 10,147 (25%; 96% allogeneic), lymphoid malignancies 26,488 (64%; 19% allogeneic), solid tumors 1,607 (3.9%; 2% allogeneic), and nonmalignant disorders 2,667 (7%; 81% allogeneic). Trends in donor choice seen before continue, with growing numbers of haploidentical HCT and decreasing use of cord blood. Of interest is that after many years of continued growth, the number of patients receiving an allogeneic HCT for marrow failure is decreasing slightly (p < 0.001). Such a change may be explained by the use of thrombopoietin analogs in aplastic anemia patients. Other nonmalignant indications, however continue to grow, most importantly HCT for hemoglobinopathies by 36%, equally for thalassemias and sickle cell disease. Non-HCT cell therapies have increased by 28% since 2015 and genetically modified T cells is type of cell therapy with the fastest growth. These annual reports reflect current activity and trends and are useful for health-care planning.
publishDate 2019
dc.date.none.fl_str_mv 2019
2019-02-06
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/10486/688585
https://dx.doi.org/10.1038/s41409-019-0465-9
url http://hdl.handle.net/10486/688585
https://dx.doi.org/10.1038/s41409-019-0465-9
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer Nature
publisher.none.fl_str_mv Springer Nature
dc.source.none.fl_str_mv reponame:Biblos-e Archivo. Repositorio Institucional de la UAM
instname:Universidad Autónoma de Madrid
instname_str Universidad Autónoma de Madrid
reponame_str Biblos-e Archivo. Repositorio Institucional de la UAM
collection Biblos-e Archivo. Repositorio Institucional de la UAM
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419966970724353
score 15,300719

Similares en LA Referencia